Dihydroartemisinin attenuates benign prostatic hyperplasia in rats by inhibiting prostatic epithelial cell proliferation
Bo Zhang, Xiang Chen, Yu Gan, Bingsheng Li, Kangning Wang, Yao He
Abstract
BACKGROUND: Benign prostatic hyperplasia (BPH) is a common urological condition in aging men. While dihydroartemisinin (DHA) exhibits a wide range of pharmacological activities, to date, there have been no studies examining the effects of DHA on BPH. METHODS: experiments to further investigate the anti-proliferative effects of DHA. RESULTS: analysis revealed that DHA significantly inhibited the proliferation of TP-treated RWPE-1 cells. CONCLUSIONS: DHA significantly inhibited the development of BPH by suppressing serum DHT levels, prostatic 5AR-2 expression, and the proliferation of benign prostatic epithelial cells. Thus, DHA is a novel medicinal agent with potential therapeutic efficacy in the treatment of patients with BPH.